ZymoGenetics' Biotech Disconnect
It's logical to think that synthetic thrombin is safer than bovine- or plasma-derived equivalents. But ZymoGenetics is finding out that it's not an easy sell, especially to Wall Street.
You may also be interested in...
Novo Nordisk's decision to spin off ZymoGenetics in 2000 was 100% inspired by Roche's hands-off relationship with Genentech. The parent claims Zymo's R&D productivity has since increased; its recent ex-US deal with Bayer-Schering on recombinant thrombin proves that Zymo has certainly grown up and left home.
The broad research, development and commercialization alliance inked in September between ZymoGenetics Inc. and Serono SA stands out not only for its size and scope--an unlimited number of proteins and up-front equity purchases and license fees totalling $81.25 million--but also because each partner is a biotech company, and the research chores will be shared from the outset.
Akili Interactive Labs, which developed the first prescription-only video-game-based platform to be cleared for marketing by the US FDA, recently announced plans to go public through a SPAC merger with Social Capital Suvretta Holdings Corp. I. See what Chamath Palihapitiya, CEO of Social Capital and CEO of Social Capital Holdings Corp. I, said about it here.